Versant Venture Management, LLC

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 12, 2025), Versant Venture Management, LLC reported 7 stock positions worth $86.7 million. Its top holding was Monte Rosa Therapeutics (GLUE) at 45.2% of the portfolio, followed by Crispr Therapeutics (CRSP, 22.6%) and Contineum Therapeutics Class A (CTNM, 15.5%). Compared with Q3 2024, it opened 2 new positions and sold out of 1. The biggest buy was a new position in Monte Rosa Therapeutics (GLUE) and the biggest sale an exit from Gritstone Bio.

Most Recent 13F
Q2 2026
Location
San Francisco, CA
CIK
0001560009
Portfolio Value
$86.7M (Q4 2024)
SEC Filing
0000950123-25-001612 ↗ filed Feb 12, 2025

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $103.1M Q1 2024 Q2 2024: $77.3M Q2 2024 Q3 2024: $63.6M Q3 2024 Q4 2024: $86.7M $86.7M Q4 2024 Q1 2025: $60.2M Q1 2025 Q2 2025: $82.1M Q2 2025 Q3 2025: $212.5M Q3 2025 Q4 2025: $151.1M Q4 2025 Q1 2026: $141.4M Q1 2026 Q2 2026: $162.6M Q2 2026

Holdings 7 stocks · $86.7M
GLUE Monte Rosa Therapeutics Inc. 45.22% 5,652,922 $39.2M New
CRSP Crispr Therapeutics AG 22.62% 498,558 $19.6M No change
CTNM Contineum Therapeutics Inc. Class A 15.51% 918,163 $13.5M No change
SKYE Skye Bioscience Inc. 6.55% 2,007,704 $5.7M No change
RPTX Repare Therapeutics Inc. 4.00% 2,646,657 $3.5M No change
TPST Tempest Therapeutics Inc. 3.37% 3,507,055 $2.9M New
ADVM Adverum Biotechnologies Inc. 2.73% 506,821 $2.4M No change

Portfolio Sells Q3 2024 → Q4 2024
GRITSTONE BIO INC Sold out 0.00% −3.25

Portfolio Buys Q3 2024 → Q4 2024
GLUE Monte Rosa Therapeutics Inc. New 45.22% +45.22
TPST Tempest Therapeutics Inc. New 3.37% +3.37

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 8$162.6MGLUE, IPSC, JBIO, LENZ, CTNM
Q1 2026 8$141.4MGLUE, IPSC, LENZ, JBIO, CTNM
Q4 2025 7$151.1MGLUE, LENZ, JBIO, CRSP, CTNM
Q3 2025 9$212.5MLENZ, GLUE, JBIO, CRSP, SKYE
Q2 2025 8$82.1MGLUE, CRSP, JBIO, SKYE, RPTX
Q1 2025 7$60.2MGLUE, CRSP, CTNM, SKYE, RPTX
Q4 2024 7$86.7MGLUE, CRSP, CTNM, SKYE, RPTX
Q3 2024 6$63.6MCRSP, CTNM, RPTX, SKYE, ADVM
Q2 2024 8$77.3MCRSP, CTNM, SKYE, RPTX, ADVM
Q1 2024 7$103.1MCRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM